Antiplatelet drug

(redirected from Antiplatelet medication)

Antiplatelet drug

Drug that inhibits platelets from aggregating to form a plug. They are used to prevent clotting and alter the natural course of atherosclerosis.
References in periodicals archive ?
When an anticoagulant or antiplatelet medication is interrupted prior to a dental procedure, there is an increased risk for thromboembolic events.
Most patients who are known to be at elevated risk for heart attack or stroke are placed on some kind of antiplatelet medication to lower their likelihood of developing an artery-blocking clot.
The authors concluded that routine dental extractions can be safely performed in patients on long-term antiplatelet medication with no interruption or alteration of their medication.
The American Heart Association (AHA) and the American College of Cardiology (ACC) in their latest guideline cited ticagrelor, an antiplatelet medication (P2Y12 inhibitor), as a preferred drug for patients with certain ACS.
Since the goal of this study was to assess association of oral anticoagulant or antiplatelet medication in BCG treated patients with prognosis, all papers not reporting any outcome correlations were excluded.
Depending on the severity of the condition, it can be managed with blood pressure drugs, antiplatelet medication to diminish risk of blood clots, balloon angioplasty or stenting to open up blood flow within the artery, and surgery to treat aneurysms.
RESULTS: Independent of antiplatelet medication, an interquartile range (IQR) increase of 39.
The study is designed to evaluate real-world clinical outcomes data for the TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient, a new antiplatelet medication.
These results "mandate continued review of guidelines for withdrawal of anticoagulant and antiplatelet medication in the peri-procedural period," Dr.
Food and Drug Administration (FDA) announced it was studying the effectiveness of the antiplatelet medication clopidogrel (Plavix) in patients taking a class of drugs known as proton-pump inhibitors (PPIs), used to treat gastroesophageal reflux disease.
With the thrombin receptor antagonist, TRA or SCH-530348, our novel investigational antiplatelet medication in late-stage development; the Merck/Schering-Plough cholesterol-lowering products VYTORIN and ZETIA; and INTEGRILIN, the leading GP IIb-IIIa inhibitor, acadesine further demonstrates our long-term commitment to developing treatments to address unmet needs in cardiac care.